Earnings Insights · GILD · Q3 FY2026
Gilead Q3 2026 Earnings: Base Business Growth Accelerates as Biktarvy Pricing Risk Comes Into Focus
By AlgovestIQ ResearchPublished
Read Gilead Sciences’s results announcement (Form 8-K, filed Oct 29, 2026)
Key earnings findings
Gilead Sciences (GILD) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Gilead Sciences reported Q3 FY2026 revenue of $8.30B against the $7.81B analyst estimate, a 6.3% beat, and EPS of $2.55 against the $2.19 analyst estimate, a 16.4% beat.
- Gilead raised its full-year 2026 product sales guidance to $31.0B to $31.3B, from $30.1B to $30.4B previously.
- GILD closed at $170.68 on Oct 30, 2026, up 3.1% from $165.61 on Oct 29, 2026, the last close before the results were released.
Sources: Gilead Sciences results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Gilead Sciences beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from -2.1% to 6.3%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Gilead Sciences reported third-quarter revenue of $8.3B, up 7% year over year, while product sales rose 13% to $8.3B. GAAP diluted EPS fell to $1.94 from $2.43, but non-GAAP EPS increased to $2.55 from $2.47 as strong HIV, Trodelvy and Livdelzi sales more than offset higher operating costs on an adjusted basis.
The central message was stronger underlying commercial momentum. Product sales excluding Veklury rose 16% to $8.2B, prompting Gilead to raise 2026 base-business sales guidance by $900M at the midpoint. The longer-term complication is now clearer: management expects Medicare pricing changes to reduce Biktarvy revenue by approximately $1.5B in 2028, although it still expects total HIV revenue, total product sales and EPS to grow that year.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $8.3B | Up 7% YoY |
| Product sales | $8.3B | Up 13% YoY |
| Product sales excluding Veklury | $8.2B | Up 16% YoY |
| GAAP diluted EPS | $1.94 | Down from $2.43 |
| Non-GAAP diluted EPS | $2.55 | Up from $2.47 |
| HIV sales | $6.2B | Up 18% YoY |
| Biktarvy sales | $4.1B | Up 10% YoY |
| Descovy sales | $1.0B | Up 49% YoY |
| Yeztugo sales | $305M | Up from $39M |
| Liver Disease sales | $927M | Up 13% YoY |
| Livdelzi sales | $203M | Up 93% YoY |
| Trodelvy sales | $506M | Up 42% YoY |
| Cell Therapy sales | $355M | Down 18% YoY |
| Veklury sales | $86M | Down 69% YoY |
| GAAP product gross margin | 81.0% | Up from 78.6% |
| Non-GAAP product gross margin | 88.1% | Up from 86.5% |
| Operating cash flow | $5.0B | Up from $4.1B |
| Free cash flow | $4.8B | Up from $4.0B |
The Bigger Story
Gilead’s quarter was defined by a substantial acceleration in its core commercial franchises rather than its reported revenue growth alone. Total revenue rose only 7% because royalty, contract and other revenue declined to $11M from $424M a year earlier, largely because prior-year revenue tied to an intellectual-property sale did not recur. Product sales, meanwhile, increased 13%, and sales excluding the declining COVID-19 treatment Veklury rose 16%.
That distinction matters. Gilead’s core growth was led by HIV, which represented roughly three-quarters of quarterly product sales, but the company also posted meaningful growth in Trodelvy and Livdelzi. Those products, together with new HIV-prevention offerings, are increasingly important to the effort to broaden growth beyond Biktarvy.
The quarter also put a number around a key longer-term risk. The U.S. Centers for Medicare and Medicaid Services set Biktarvy’s Maximum Fair Price at $2,600 per 30-day supply, effective January 2028. Management said the resulting net impact on Biktarvy revenue could be approximately $1.5B in 2028, including the lower Medicare price and spillover effects across Medicaid, 340B and other U.S. channels.
Revenue and Operating Performance
HIV remained the primary driver of the quarter, with sales increasing 18% to $6.2B. Management attributed the performance to higher demand, higher average realized prices and favorable inventory dynamics. It also cautioned that inventory levels were higher than usual in the third quarter and are expected to normalize by year-end, which may temper the usual fourth-quarter inventory build.
Biktarvy sales rose 10% to $4.1B. Demand and pricing contributed, while favorable inventory also aided growth. Management said Biktarvy reached a 53% U.S. treatment market share, supported by new-patient gains, patient retention and improved access after changes to Florida’s AIDS Drug Assistance Program. The HIV treatment market has not returned to its historical 2% to 3% growth rate, according to management, although it has shown signs of stabilization.
Descovy revenue increased 49% to $1.0B, supported by pricing and inventory dynamics. Management said PrEP accounted for approximately 80% of Descovy sales. Yeztugo, Gilead’s long-acting HIV-prevention product, generated $305M in sales, versus $39M a year earlier, and management continues to target roughly $1B of full-year sales. Yeztugo and Descovy for PrEP together held 50% of the PrEP market, according to management.
Outside HIV, Trodelvy sales climbed 42% to $506M on demand growth in metastatic triple-negative breast cancer and HR-positive/HER2-negative breast cancer. Management characterized the product as operating at an approximately $2B annual sales run rate. European approval of Trodelvy plus Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer expands the product’s addressable first-line population, although the contribution from that indication will depend on uptake and reimbursement.
Livdelzi sales increased 93% to $203M, helping lift Liver Disease sales 13% to $927M. The product is gaining demand in primary biliary cholangitis, while the broader liver portfolio also benefited from favorable realized pricing in hepatitis B and hepatitis C products. Lower demand for HCV therapies partly offset those gains.
The weaker areas remained predictable. Cell Therapy sales declined 18% to $355M amid ongoing competitive pressure. Veklury sales fell 69% to $86M as COVID-19-related hospitalizations declined. Those declines reinforce why investors will focus on the durability of HIV growth and whether oncology launches can offset pressure on legacy and cell-therapy products.
Profitability and Margins
GAAP diluted EPS declined 20% to $1.94. The lower result reflected losses on equity securities compared with gains a year earlier, higher operating expenses, a higher tax rate and sharply lower royalty and contract revenue. These factors more than offset higher product sales and lower acquired in-process R&D expense in the quarter.
Non-GAAP diluted EPS rose 3% to $2.55. Management noted that third-quarter 2025 included approximately $400M, or $0.25 per share, of royalty and other revenue related to a prior intellectual-property asset sale. Excluding that contribution, management said adjusted EPS rose 15% year over year.
Gross margin improved, with GAAP product gross margin increasing 240 basis points to 81.0% and non-GAAP margin rising 160 basis points to 88.1%. The improvement primarily reflected the expiration of a royalty-related obligation.
The margin improvement did not translate into broad operating leverage during the quarter. R&D expense increased 19% to $1.6B, driven by employee-related and clinical-material costs. SG&A rose 21% to $1.6B, reflecting HIV promotional activity, integration costs from recent acquisitions, legal expenses and employee-related costs. On a non-GAAP basis, operating margin was 50.2%, essentially flat with 50.5% a year earlier.
Demand, Customers and Pricing
The quality of the HIV result was strong, but not entirely volume-driven. Pricing and inventory benefited Biktarvy and Descovy, and management expects the unusual third-quarter inventory contribution to normalize by year-end. That makes underlying demand, market share and persistence more useful indicators of the franchise’s sustainable growth rate.
In HIV prevention, management said Yeztugo has become the leading long-acting injectable option. More than 70% of users returned for a second injection, supporting the company’s claim of strong persistence. The mix of new starts also improved, with a growing share of PrEP-naive users alongside patients switching from existing regimens.
Gilead launched Bixlenvo in August for virologically suppressed adults switching from existing HIV regimens. Management said early uptake among patients on complex regimens was in line with expectations, though the product’s financial contribution was modest in the third quarter.
What is Gilead’s guidance for full-year 2026?
Gilead raised its full-year 2026 product sales guidance to $31.0B to $31.3B, from $30.1B to $30.4B previously. Product sales excluding Veklury are now expected to reach $30.7B to $31.0B, up from the prior range of $29.8B to $30.1B. Veklury guidance was unchanged at approximately $300M.
Management expects HIV sales to grow approximately 12% for the full year, supported by Biktarvy, Yeztugo and Descovy. It continues to expect Yeztugo sales of approximately $1B and a mid-teens percentage decline in Cell Therapy sales.
However, Gilead lowered its earnings outlook to reflect business-development charges. It now expects a GAAP loss per share of $4.40 to $4.05 and a non-GAAP loss per share of $1.20 to $0.85, compared with prior non-GAAP loss guidance of $0.65 to $0.30.
The outlook includes approximately $12.4B of acquired IPR&D charges related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions, net of the Lakefront collaboration and related taxes. Management now expects acquired IPR&D of approximately $12.9B, including anticipated fourth-quarter upfront payments related to PepStar and the Vir Biotechnology collaboration.
Balance Sheet, Cash Flow and Capital
Gilead generated $5.0B of operating cash flow and $4.8B of free cash flow in the third quarter. For the first nine months of 2026, operating cash flow reached $11.2B and free cash flow totaled $10.7B.
Cash, cash equivalents and marketable debt securities were $6.4B at September 30, down from $10.6B at year-end 2025. The reduction reflected $11.3B of acquisition-related outflows, $2.8B of debt repayments, $3.1B of dividend payments and $1.1B of share repurchases, partly offset by operating cash flow and $4.1B of net debt-financing proceeds.
During the quarter, Gilead returned approximately $1.4B to shareholders through $1.0B in dividends and $370M in repurchases. The company also declared a fourth-quarter dividend of $0.82 per share.
What Investors Should Watch
1. HIV growth after inventory normalization
Third-quarter HIV growth benefited from inventory dynamics and pricing. Investors should watch whether Biktarvy, Descovy and Yeztugo can sustain strong demand-driven growth once those temporary inventory effects fade.
2. The 2028 Biktarvy pricing impact
Management’s preliminary estimate of a $1.5B Biktarvy revenue impact in 2028 is now the principal known pressure on the company’s largest product. The key issue is whether PrEP growth, new HIV treatment launches and expansion outside HIV can offset that headwind as expected.
3. Yeztugo’s trajectory toward $1B
Yeztugo’s rapid ramp is strategically important because it broadens Gilead’s HIV business beyond daily treatment. Sales progression, reinjection persistence, PrEP-naive adoption and payer coverage will determine whether the product can meet management’s full-year target and support longer-term prevention growth.
4. Cell Therapy stabilization and anito-cel’s launch
Cell Therapy revenue remains under pressure, down 18% in the quarter. The FDA’s December 23 decision date for anito-cel in later-line multiple myeloma is a major near-term milestone, but launch execution and competitive positioning will determine whether it can restore growth in the franchise.
5. Pipeline spending and acquired IPR&D
Gilead’s acquisitions have expanded its oncology and inflammation pipeline but also drive a large 2026 earnings loss through acquired IPR&D charges. Investors should monitor clinical progress, integration and whether the acquired programs produce differentiated data sufficient to justify the capital deployed.
AlgovestIQ Takeaway
Gilead’s third quarter showed that its commercial base is growing faster than the headline revenue figure suggests. Core product sales excluding Veklury rose 16%, with broad contributions from HIV, Trodelvy and Livdelzi. The revenue increase was not solely dependent on a single product, although Biktarvy remains the company’s largest profit and sales driver.
The main improvement in the investment case is the increased evidence that HIV prevention can become a meaningful second growth pillar within the HIV franchise. Yeztugo’s early sales ramp, Descovy’s continued PrEP growth and the planned weekly and annual lenacapavir options provide Gilead with several potential ways to grow even as daily-treatment pricing faces pressure.
Still, the quarter also clarified the scale of Gilead’s Biktarvy exposure. The expected $1.5B revenue impact from Medicare pricing changes in 2028 is material, and management’s expectation of overall HIV and companywide growth in that year depends on product launches, market adoption and continued execution across several franchises.
The central investment question is no longer whether Gilead can generate near-term growth. The quarter suggests it can. It is whether HIV prevention, next-generation HIV treatment, Trodelvy, inflammation assets and anito-cel can collectively create enough durable growth to offset Biktarvy’s 2028 pricing reset while preserving the company’s historically strong margin and cash-generation profile.
How did GILD stock react?
GILD closed at $170.68 on Oct 30, 2026, up 3.1% from $165.61 on Oct 29, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Oct 29, 2026 (before release) | $165.61 | — |
| Oct 30, 2026 | $170.68 | +3.1% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- LLYEli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B QuarterOct 29, 2026
- MRKMerck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPSOct 29, 2026
- ABBVAbbVie Q3 2026 Earnings: Skyrizi and Rinvoq Drive Another Guidance IncreaseOct 30, 2026
- BIIBBiogen Q3 2026 Earnings: Apellis Lifts Revenue Growth, but Acquisition Costs Depress EPSOct 28, 2026
- PFEPfizer Q3 2026 Earnings: Core Products Offset COVID Declines as Guidance RisesNov 3, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Gilead Sciences Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Gilead Sciences Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.